Pancreatic Cancer Research

ResearcherPhilipps University of MarburgActive in the last 2 years

Thomas P. Potjer

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3831-6022; OpenAlex author ID A5053853285. Sources: OpenAlex.

Their work

Papers
14 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 2 papers · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 3 papers

Papers 14

  1. Psychosocial issues of individuals undergoing surveillance for increased risk of melanoma and pancreatic cancer due to a germline CDKN2A variant: A focus group… Co-author DOI 10.1002/jgc4.1820↗
  2. The Added Value of Blood Glucose Monitoring in High-Risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1097/mpa.0000000000002335↗
  3. Utilization and Outcomes of Multigene Panel Testing in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/op.23.00447↗
  4. Surveillance for Pancreatic Cancer in High-Risk Individuals Leads to Improved Outcomes: A Propensity Score-Matched Analysis. Co-author DOI 10.1053/j.gastro.2023.02.032↗
  5. Pancreatic cancer surveillance and its ongoing challenges: is it time to refine our eligibility criteria? Co-author DOI 10.1136/gutjnl-2021-324739↗
  6. Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up. Co-author DOI 10.1200/jco.22.00194↗
  7. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic CDKN2A variants. Last author DOI 10.1136/jmedgenet-2019-106562↗
  8. Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutati… Co-author DOI 10.1007/s10689-019-00137-5↗
  9. Targeted next-generation sequencing of FNA-derived DNA in pancreatic cancer. Co-author DOI 10.1136/jclinpath-2016-203928↗
  10. Application of a Serum Protein Signature for Pancreatic Cancer to Separate Cases from Controls in a Pancreatic Surveillance Cohort. Co-author DOI 10.1016/j.tranon.2016.03.003↗
  11. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. Co-author DOI 10.1200/jco.2015.64.0730↗
  12. Limited resection of pancreatic cancer in high-risk patients can result in a second primary. Co-author DOI 10.1136/gutjnl-2015-309568↗
  13. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study. Co-author DOI 10.1186/s13104-015-1235-4↗
  14. Variation in precursor lesions of pancreatic cancer among high-risk groups. Co-author DOI 10.1158/1078-0432.ccr-12-2730↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Monique Esther van Leerdam · 5 shared papers, 2022–2024 · strength 0.90
  2. Derk C.F. Klatte · 5 shared papers, 2022–2024 · strength 0.90
  3. Hans F. A. Vasen · 10 shared papers, 2013–2024 · strength 0.87
  4. Bert A. Bonsing · 8 shared papers, 2013–2024 · strength 0.71
  5. Jeanin Elise van Hooft · 4 shared papers, 2022–2024 · strength 0.66
  6. Martin N.J.M. Wasser · 5 shared papers, 2013–2024 · strength 0.53
  7. J. Sven D. Mieog · 4 shared papers, 2017–2024 · strength 0.52
  8. Bas Boekestijn · 3 shared papers, 2022–2024 · strength 0.46
  9. Hans Morreau · 5 shared papers, 2013–2023 · strength 0.41
  10. Eveline M. A. Bleiker · 1 shared paper, 2024 · strength 0.24
  11. Douglas L. Riegert‐Johnson · 1 shared paper, 2024 · strength 0.20
  12. Jason Scott Starr · 1 shared paper, 2024 · strength 0.20
  13. Michael B. Wallace · 1 shared paper, 2024 · strength 0.20
  14. Yan Bi · 1 shared paper, 2024 · strength 0.20
  15. Aleksander M. Bogdanski · 1 shared paper, 2024 · strength 0.18
  16. Isaura S. Ibrahim · 2 shared papers, 2016–2022 · strength 0.17
  17. Frederik Jan Hes · 2 shared papers, 2015–2021 · strength 0.16
  18. Lydia G. van der Geest · 1 shared paper, 2023 · strength 0.15
  19. Detlef Klaus Bartsch · 3 shared papers, 2013–2016 · strength 0.13
  20. Emily P. Slater · 3 shared papers, 2013–2016 · strength 0.13
  21. Kasper A. Overbeek · 1 shared paper, 2021 · strength 0.12
  22. Marco J. Bruno · 1 shared paper, 2021 · strength 0.12
  23. Djuna L. Cahen · 1 shared paper, 2021 · strength 0.12
  24. Nelleke A. Gruis · 1 shared paper, 2019 · strength 0.11
  25. Eirini Christodoulou · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.